Association Between Elevated suPAR, a New Biomarker of Inflammation, and Accelerated Aging.
Gait speed
Immunosenescence
Inflammaging
MRI
Pace of aging
Journal
The journals of gerontology. Series A, Biological sciences and medical sciences
ISSN: 1758-535X
Titre abrégé: J Gerontol A Biol Sci Med Sci
Pays: United States
ID NLM: 9502837
Informations de publication
Date de publication:
18 01 2021
18 01 2021
Historique:
received:
10
03
2020
pubmed:
9
8
2020
medline:
15
7
2021
entrez:
9
8
2020
Statut:
ppublish
Résumé
To understand and measure the association between chronic inflammation, aging, and age-related diseases, broadly applicable standard biomarkers of systemic chronic inflammation are needed. We tested whether elevated blood levels of the emerging chronic inflammation marker soluble urokinase plasminogen activator receptor (suPAR) were associated with accelerated aging, lower functional capacity, and cognitive decline. We used data from the Dunedin Study, a population-representative 1972-1973 New Zealand birth cohort (n = 1037) that has observed participants to age 45 years. Plasma suPAR levels were analyzed at ages 38 and 45 years. We performed regression analyses adjusted for sex, smoking, C-reactive protein, and current health conditions. Of 997 still-living participants, 875 (88%) had plasma suPAR measured at age 45. Elevated suPAR was associated with accelerated pace of biological aging across multiple organ systems, older facial appearance, and with structural signs of older brain age. Moreover, participants with higher suPAR levels had greater decline in physical function and cognitive function from childhood to adulthood compared to those with lower suPAR levels. Finally, improvements in health habits between ages 38 and 45 (smoking cessation or increased physical activity) were associated with less steep increases in suPAR levels over those years. Our findings provide initial support for the utility of suPAR in studying the role of chronic inflammation in accelerated aging and functional decline.
Sections du résumé
BACKGROUND
To understand and measure the association between chronic inflammation, aging, and age-related diseases, broadly applicable standard biomarkers of systemic chronic inflammation are needed. We tested whether elevated blood levels of the emerging chronic inflammation marker soluble urokinase plasminogen activator receptor (suPAR) were associated with accelerated aging, lower functional capacity, and cognitive decline.
METHODS
We used data from the Dunedin Study, a population-representative 1972-1973 New Zealand birth cohort (n = 1037) that has observed participants to age 45 years. Plasma suPAR levels were analyzed at ages 38 and 45 years. We performed regression analyses adjusted for sex, smoking, C-reactive protein, and current health conditions.
RESULTS
Of 997 still-living participants, 875 (88%) had plasma suPAR measured at age 45. Elevated suPAR was associated with accelerated pace of biological aging across multiple organ systems, older facial appearance, and with structural signs of older brain age. Moreover, participants with higher suPAR levels had greater decline in physical function and cognitive function from childhood to adulthood compared to those with lower suPAR levels. Finally, improvements in health habits between ages 38 and 45 (smoking cessation or increased physical activity) were associated with less steep increases in suPAR levels over those years.
CONCLUSIONS
Our findings provide initial support for the utility of suPAR in studying the role of chronic inflammation in accelerated aging and functional decline.
Identifiants
pubmed: 32766674
pii: 5872539
doi: 10.1093/gerona/glaa178
pmc: PMC7812430
doi:
Substances chimiques
Biomarkers
0
Inflammation Mediators
0
PLAUR protein, human
0
Receptors, Urokinase Plasminogen Activator
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
318-327Subventions
Organisme : NIA NIH HHS
ID : R01 AG032282
Pays : United States
Organisme : NIA NIH HHS
ID : R01 AG049789
Pays : United States
Organisme : Medical Research Council
ID : MR/P005918
Pays : United Kingdom
Informations de copyright
© The Author(s) 2020. Published by Oxford University Press on behalf of The Gerontological Society of America.
Références
Soc Psychiatry Psychiatr Epidemiol. 2015 May;50(5):679-93
pubmed: 25835958
Circulation. 2003 Jan 28;107(3):363-9
pubmed: 12551853
Mol Psychiatry. 2019 Dec 10;:
pubmed: 31822815
Am J Cardiol. 2012 Dec 15;110(12):1756-63
pubmed: 22981263
N Engl J Med. 2015 Nov 12;373(20):1916-25
pubmed: 26539835
J Gerontol A Biol Sci Med Sci. 2014 Jun;69 Suppl 1:S1-3
pubmed: 24833579
J Gerontol A Biol Sci Med Sci. 2019 Mar 14;74(4):469-479
pubmed: 30084875
Nat Hum Behav. 2020 Mar;4(3):255-264
pubmed: 31959926
Int J Cancer. 2017 Jul 1;141(1):191-199
pubmed: 28393357
Br J Nutr. 2019 Mar;121(6):699-708
pubmed: 30626457
Exp Gerontol. 2018 May;105:4-9
pubmed: 29111233
Proc Natl Acad Sci U S A. 2015 Jul 28;112(30):E4104-10
pubmed: 26150497
J Gerontol A Biol Sci Med Sci. 2014 Jun;69 Suppl 1:S4-9
pubmed: 24833586
J Intern Med. 2010 Sep;268(3):296-308
pubmed: 20561148
JAMA Pediatr. 2019 Nov 4;:1-11
pubmed: 31682707
Med Sci Sports Exerc. 2000 Sep;32(9 Suppl):S498-504
pubmed: 10993420
Cell. 2013 Jun 6;153(6):1194-217
pubmed: 23746838
N Engl J Med. 2020 Jan 30;382(5):416-426
pubmed: 31995687
J Geriatr Phys Ther. 2007;30(1):8-15
pubmed: 19839175
Sci Rep. 2017 Jan 16;7:40627
pubmed: 28091558
Transl Res. 2013 Nov;162(5):287-96
pubmed: 23916811
Proc Natl Acad Sci U S A. 2016 May 31;113(22):E3071-80
pubmed: 27185911
Arch Phys Med Rehabil. 1985 Feb;66(2):69-74
pubmed: 3970660
J Child Psychol Psychiatry. 2019 Feb;60(2):199-208
pubmed: 29741788
J Am Med Dir Assoc. 2013 Dec;14(12):877-82
pubmed: 23792036
Phys Ther. 1984 Jul;64(7):1067-70
pubmed: 6739548
Res Q Exerc Sport. 1999 Jun;70(2):113-9
pubmed: 10380242
Infect Immun. 2000 Apr;68(4):2156-60
pubmed: 10722614
J Gerontol A Biol Sci Med Sci. 2019 Feb 15;74(3):343-349
pubmed: 29534173
BMC Med. 2012 Jan 05;10:2
pubmed: 22221662
Immun Ageing. 2019 Jan 22;16:1
pubmed: 30679937
PLoS One. 2014 Oct 20;9(10):e110555
pubmed: 25329298
Nat Med. 2019 Dec;25(12):1822-1832
pubmed: 31806905
Nat Med. 2019 Mar;25(3):487-495
pubmed: 30842675
JAMA. 1999 Feb 10;281(6):558-60
pubmed: 10022113
Crit Rev Clin Lab Sci. 2017 Mar;54(2):117-133
pubmed: 28084848
Stroke. 2014 Jan;45(1):18-23
pubmed: 24253546
JAMA Netw Open. 2019 Oct 2;2(10):e1913123
pubmed: 31603488
Int J Cardiol. 2013 Aug 10;167(3):781-5
pubmed: 22459389
J Gerontol A Biol Sci Med Sci. 2019 Oct 4;74(11):1716-1724
pubmed: 31107949
Int J Audiol. 2008 Feb;47(2):67-75
pubmed: 18236239
BMC Cancer. 2011 Oct 14;11:448
pubmed: 21999221
Ann Neurol. 2015 Apr;77(4):607-17
pubmed: 25601795
Emerg Med J. 2016 Nov;33(11):769-775
pubmed: 27590986
Science. 2014 Oct 31;346(6209):587-91
pubmed: 25359967
Neuroimage. 2017 Mar 1;148:179-188
pubmed: 27890805
Dis Markers. 2009;27(3):157-72
pubmed: 19893210
Eur J Clin Invest. 2016 Apr;46(4):305-11
pubmed: 26799247
Int J Cancer. 2015 Nov 15;137(10):2470-7
pubmed: 25664394
J Gerontol A Biol Sci Med Sci. 2019 Feb 15;74(3):283-289
pubmed: 29985987